Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

132 Applying Pharmacogenomics in Therapeutics
6. The derivative chromosome 22 resulted from translocation between
chromosomes 9 and 22 is known as Philadelphia chromosome. The fusion
gene on Ph is BCR/ABL, which serves as drug target for the treatment
of CML.
7. Fluorescence in situ hybridization (FISH).
8. p.L858R point mutation in exon 21 and small deletions in exon 19 (Del19).
9. BRCA1 and BRCA2.
REFERENCES
Advani, A.S., and Pendergast, A.M. (2002). Bcr-Abl variants: Biological and clinical aspects.
Leukemia Research 26, 713–720.
American Society of Clinical Oncology. (1996). Statement of the American Society of
Clinical Oncology: Genetic testing for cancer susceptibility, Adopted on February 20,
1996. Journal of Clinical Oncology 14, 1730–1736.
American Society of Clinical Oncology. (2003). American Society of Clinical Oncology
policy statement update: Genetic testing for cancer susceptibility. Journal of Clinical
Oncology 21, 2397–2406.
Andersen, S.W., Trentham-Dietz, A., Figueroa, J.D., Titus, L.J., Cai, Q., Long, J., Hampton,
J.M., Egan, K.M., and Newcomb, P.A. (2013). Breast cancer susceptibility associated
with rs1219648 (fibroblast growth factor receptor 2) and postmenopausal hormone therapy
use in a population-based United States study. Menopause 20, 354–358.
Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A.,
Saitoh, S., Shimokata, K., and Hasegawa, Y. (2000). Polymorphisms of UDPglucuronosyltransferase
gene and irinotecan toxicity: A pharmacogenetic analysis.
Cancer Research 60, 6921–6926.
Antoniou, A., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Loman, N.,
et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or
BRCA2 mutations detected in case series unselected for family history: A combined
analysis of 22 studies. American Journal of Human Genetics 72, 1117–1130.
Baker, K.E., and Parker, R. (2004). Nonsense-mediated mRNA decay: Terminating erroneous
gene expression. Current Opinion in Cell Biology 16, 293–299.
Ball, S.E., Scatina, J., Kao, J., Ferron, G.M., Fruncillo, R., Mayer, P., Weinryb, I., et al.
(1999). Population distribution and effects on drug metabolism of a genetic variant
in the 5′ promoter region of CYP3A4. Clinical Pharmacology and Therapeutics 66,
288–294.
Baselga, J., Norton, L., Albanell, J., Kim, Y.M., and Mendelsohn, J. (1998). Recombinant
humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel
and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.
Cancer Research 58, 2825–2831.
Bell, D.A., Badawi, A.F., Lang, N.P., Ilett, K.F., Kadlubar, F.F., and Hirvonen, A. (1995).
Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: Association
of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue.
Cancer Research 55, 5226–5229.
Beutler, E., Gelbart, T., and Demina, A. (1998). Racial variability in the UDPglucuronosyltransferase
1 (UGT1A1) promoter: A balanced polymorphism for regulation
of bilirubin metabolism? Proceedings of the National Academy of Sciences of the
United States of America 95, 8170–8174.
Beyth, R.J., Quinn, L., and Landefeld, C.S. (2000). A multicomponent intervention to prevent
major bleeding complications in older patients receiving warfarin. A randomized, controlled
trial. Annals of Internal Medicine 133, 687–695.